AtriCure (NASDAQ:ATRC) Lowered to “Hold” Rating by Zacks Research

Zacks Research cut shares of AtriCure (NASDAQ:ATRC) from a strong-buy rating to a hold rating in a report published on Monday,Zacks.com reports.

Several other research firms have also issued reports on ATRC. Wall Street Zen lowered shares of AtriCure from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 2nd. UBS Group reduced their target price on shares of AtriCure from $55.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, July 28th. Canaccord Genuity Group upped their price target on shares of AtriCure from $53.00 to $55.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. BTIG Research increased their price target on AtriCure from $45.00 to $55.00 and gave the company a “buy” rating in a report on Monday. Finally, Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, August 19th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.62.

AtriCure Stock Performance

AtriCure stock opened at $48.68 on Monday. The stock’s 50-day moving average is $36.67 and its 200-day moving average is $31.97. The company has a market cap of $2.48 billion, a price-to-earnings ratio of 231.82 and a beta of 1.20. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. AtriCure has a 12 month low of $25.36 and a 12 month high of $49.88.

AtriCure (NASDAQ:ATRC) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The business had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a return on equity of 2.34% and a net margin of 1.85%.During the same quarter in the previous year, the business earned ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts anticipate that AtriCure will post 0.2 earnings per share for the current year.

Insider Activity at AtriCure

In other news, Director Sven Wehrwein sold 25,000 shares of the business’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $37.84, for a total transaction of $946,000.00. Following the transaction, the director directly owned 40,518 shares of the company’s stock, valued at approximately $1,533,201.12. The trade was a 38.16% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of the company’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $38.80, for a total transaction of $239,861.60. Following the completion of the transaction, the insider owned 100,219 shares of the company’s stock, valued at $3,888,497.20. This trade represents a 5.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 44,246 shares of company stock valued at $1,691,895. 4.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On AtriCure

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its holdings in AtriCure by 1.0% in the first quarter. AQR Capital Management LLC now owns 83,685 shares of the medical device company’s stock valued at $2,700,000 after purchasing an additional 837 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of AtriCure by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,146 shares of the medical device company’s stock worth $908,000 after purchasing an additional 1,230 shares during the last quarter. Goldman Sachs Group Inc. grew its stake in AtriCure by 1.0% in the first quarter. Goldman Sachs Group Inc. now owns 862,668 shares of the medical device company’s stock worth $27,830,000 after purchasing an additional 8,956 shares in the last quarter. Jane Street Group LLC raised its stake in AtriCure by 658.3% during the first quarter. Jane Street Group LLC now owns 100,853 shares of the medical device company’s stock valued at $3,254,000 after buying an additional 87,553 shares in the last quarter. Finally, Strs Ohio bought a new stake in shares of AtriCure in the 1st quarter valued at approximately $158,000. 99.11% of the stock is owned by hedge funds and other institutional investors.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.